Amarin Corp Plc (AMRN)

[sstyles]

Cantor Call - I was somewhat surprised the lawyer on the call thought the question of obviousness was such a close one in terms of invalidating the patents. The lawyer indicated the generics were relying on Mori to show that it was obvious that EPA would lower TGs without raising LDL levels even though Mori was a different patient population. Lawyer seems to think Mori could be compelling for the generics in terms of showing obviousness.

While the generics have the burden here on obviousness and given the high clear and convincing standard, the question is will Judge Du really want to invalidate the patents and in doing so indicate that the USPTO examiner got it wrong.

As the lawyer pointed out Judge Du is a young judge, appears to be by the book, and she does not want to be reversed on appeal. While trials always carry risk, it is hard to believe she is going to go against the USPTO office and invalidate the patents. That truly would be bucking the system and against convention.